Biosimilars

Biologicals patent expiries

Biosimilars/General | Posted 13/11/2015

Biosimilars are now a reality. The European Medicines Agency (EMA) approved its first biosimilar back in 2006 [1] and, with the increasing price of new biologicals and continuing pressure on healthcare budgets, biosimilars are expected to make up an increasing share of the biologicals market.

Biosimilars and interchangeability

Biosimilars/Research | Posted 13/11/2015

In a study by researchers from the Tufts Center for the Study of Drug Development (Tufts CSDD) the question of interchangeability around the world was one of the topics investigated [1].

Economic considerations for rheumatoid arthritis biosimilars

Biosimilars/Research | Posted 13/11/2015

In the paper by Gulácsi et al. [1], the authors stated that biosimilars have the potential to reduce costs and increase patient access to biologicals in the treatment of rheumatoid arthritis (RA) and other chronic inflammatory rheumatic and bowel diseases.

Formycon starts phase III trial for ranibizumab biosimilar

Biosimilars/News | Posted 13/11/2015

German biosimilars companies Formycon and Bioeq announced on 7 October 2015 that they had initiated a pivotal phase III clinical trial with their candidate ranibizumab biosimilar (FYB201).

Non-originator low molecular weight heparins: generics or biosimilars

Biosimilars/Research | Posted 06/11/2015

First developed in the 1980s, low molecular weight heparins (LMWHs) are complex anticoagulants derived from porcine intestinal mucosa and are used in the treatment of deep vein thrombosis and pulmonary embolism. Heparin sodium’s anticoagulant activity is mainly governed by its ability to bind to the serine protease inhibitor antithrombin (AT). In this sense, heparin sodium functions as a cofactor for AT by modifying its conformation, thereby accelerating the inactivation of clotting factors.

Positive phase I results for adalimumab biosimilar

Biosimilars/Research | Posted 06/11/2015

In an announcement on 28 October 2015, biopharmaceutical specialist Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) claimed that results from a phase I study of its adalimumab biosimilar (BI 695501) had ‘demonstrated pharmacokinetic bioequivalence’ to Humira (adalimumab).

Biosimilar naming and AE reporting

Biosimilars/Research | Posted 30/10/2015

How will biosimilar naming affect the ability to attribute adverse events (AEs) to a particular product? This is a question researchers from the Tufts Center for the Study of Drug Development (Tufts CSDD) sought to answer [1].

Biosimilars of ranibizumab

Biosimilars/General | Posted 30/10/2015

Last update: 4 December 2020

Ranibizumab is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab. Ranibizumab inhibits angiogenesis (the formation of new blood vessels) by inhibiting vascular endothelial growth factor A (VEGF-A), a mechanism similar to bevacizumab [1].

Boehringer Ingelheim stops biosimilar rituximab development

Biosimilars/News | Posted 30/10/2015

Germany-based Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) has reportedly halted clinical development for its biosimilar version (BI 695500) of Roche’s blockbuster leukaemia treatment Rituxan/MabThera (rituximab).

Rituximab biosimilar claimed similar pharmacokinetics to originator

Biosimilars/Research | Posted 30/10/2015

A phase I/II study of Pfizer’s rituximab biosimilar candidate PF-05280586 has shown similar pharmacokinetic (PK) properties, according to Jacobs and co-authors [1].